NDATOPICALCREAM
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ABREVA (docosanol) by GSK. Approved for cold sores/fever blisters on the face, lips shortens healing time, duration of symptoms: tingling and 3 more indications. First approved in 2000.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABREVA (docosanol) is a topical antiviral cream approved for treating cold sores and fever blisters on the face and lips. It shortens healing time and reduces symptom duration including tingling, pain, burning, and itching. The mechanism of action involves inhibition of viral entry and replication at the cellular membrane.
LOE Approaching
Product is in late-stage commercial maturity with declining franchise momentum; teams are typically lean and focused on cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ABREVA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.